CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-18). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2768 · Search date 2026-08-18 · Methodology v0.7

Energy-dense enteral nutrition,
does it really help with Reduced 90-day mortality in mechanically ventilated critically ill adults?

30-Second Summary
D
Evidence Grade D · 34 · Safety caution
Calorie delivery increased, but 90-day survival did not improve
Vomiting or regurgitation occurred in 18.9% versus 15.7%, and insulin use in 55.8% versus 49.0%, both more frequent with energy-dense feeding. The reported serious adverse event of bowel ischemia occurred once in each group.
What the
research shows
The grade is D. In the actual TARGET analysis of 90-day mortality, deaths were 523/1,948 (26.8%) with energy-dense nutrition versus 505/1,966 (25.7%) with routine nutrition, an absolute difference of +1.2 points, RR 1.05 (95% CI 0.94 to 1.16), p=0.41. This large double-blind trial found no survival benefit, but its power assumption was not a validated minimum important difference, so meaningful benefit was not definitively excluded; the result is D with 34 points.
What the
ads claim
The trial does not support a claim that meeting a higher calorie target improves survival. A denser formula increased calorie delivery at the same target rate, but did not reduce 90-day mortality.
*

Useful facts when choosing a product

  • The trial formulas contained 1.5 and 1.0 kcal/mL, with similar protein concentrations of 56 and 55 g/L.
  • Trial nutrition continued for up to 28 days or until enteral feeding stopped, death, or ICU discharge.
  • Both formulas supplied by Fresenius Kabi were randomized intervention materials, not assessment tools.
Gap Measurement · Verdict 2768 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

There were 4,000 randomization events, with three patients randomized twice, leaving 3,997 randomized patients. The prespecified modified intention-to-treat population was 3,957, 1,971 versus 1,986; the actual 90-day primary analysis included 3,914, 1,948 versus 1,966. Australia's NHMRC and New Zealand's Health Research Council provided grants. Fresenius Kabi Deutschland provided in-kind supply and delivery of both trial formulas, which were intervention materials rather than assessment tools. The company reviewed and commented on the manuscript, while investigators designed, conducted, analyzed, and decided to submit the trial. Axis 6 B0 evidence ① Allocation concealment: "Concealment of the treatment assignments was maintained with a secure, Web-based randomization system, which was accessible 24 hours a day." ② Blinding: "We conducted an investigator-initiated, randomized, double-blind, pragmatic trial"; "The formulations were indistinguishable in color and packaging." ③ Analysis population and missing data: "All analyses were conducted with the use of a modified intention-to-treat principle."; "No imputation was used to estimate missing data, and analyses were based on all available data with numbers of available observations reported." ④ Prespecified primary endpoint: "The primary outcome was all-cause mortality within 90 days after randomization." — consistent with registration NCT02306746

02

Why this is classified as D (34)

A large double-blind hard-outcome trial found no survival benefit and left benefit possible, giving D with 34 points. Secure web allocation, blinding, prespecified modified intention-to-treat analysis and missing-data handling, and a registry-consistent primary endpoint were documented.

Counterpoint. This verdict is limited to 90-day survival. Specific deficiency states, protein dose, and long-term functional recovery are separate questions.

Rejudgment record. Cross-check applied — Centers the actual 3,914-person 90-day mortality analysis and its absolute and relative estimates while accounting for mixed funding, in-kind intervention supply, and four directly documented trial-quality requirements

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Energy-dense enteral nutrition reduces 90-day mortalityDMortality was 26.8% versus 25.7%, RR 1.05, with no benefit.
Energy-dense enteral nutrition increases delivered caloriesBIt delivered a mean 601 kcal/day more from trial nutrition.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
TARGET Investigators. 2018 TARGETDouble-blind pragmatic randomized trial in 46 Australian and New Zealand ICUs1,966Grants from Australia's NHMRC and New Zealand's Health Research Council plus in-kind supply and delivery of both trial formulas by Fresenius Kabi DeutschlandAll-cause mortality within 90 days after randomization523/1,948 (26.8%) versus 505/1,966 (25.7%); absolute difference +1.2 points; RR 1.05 (95% CI 0.94 to 1.16), p=0.41Large rigorously designed null hard-outcome trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

TARGET Investigators, for the ANZICS Clinical Trials Group; Chapman M, Peake SL, Bellomo R, et al. Energy-Dense versus Routine Enteral Nutrition in the Critically Ill. N Engl J Med. 2018;379(19):1823-1834. PMID: 30346225. DOI: 10.1056/NEJMoa1811687. NCT02306746.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none

Cite this verdict

Energy-dense enteral nutrition x 90-day mortality in mechanically ventilated critical illness Evidence Grade D card
[Chamgap] Energy-dense enteral nutrition x 90-day mortality in mechanically ventilated critical illness — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/energy-dense-enteral-nutrition-critically-ill-90-day-mortality/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.